SSTR1 and glioblastoma: In fact, we had the opportunity to use specific SSTRs-agonists and found that the agonists targeting SSTR1, SSTR2, and SSTR5, but not SSTR3, also exerted antiproliferative effects in GBM-cells, being the most effective the SSTR2-agonist.